MedTrace Logo

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

NCT04700488 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

Conditions

  • PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

6D-MRI

Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Stephen Pandol, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04700488 on ClinicalTrials.gov